HUM

HumanaB

NYSE / Health Care Equipment & Services

At close

2026-06-02

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

25%

Probability

Target price

$265.00

-17.4% vs current

Most likely

Base case

45%

Probability

Target price

$215.00

-33.0% vs current

B-

Bear case

30%

Probability

Target price

$180.00

-43.9% vs current

AI sentiment snapshot

Latest data as of 2026-04-29

AI commentary

This is a T+1 earnings follow-up dated April 29, 2026. Tone is mixed-to-cautious: recent news coverage framed the quarter as an EPS beat, but the stock reaction was negative because adjusted FY2026 guidance was not raised and GAAP guidance was reduced. Headline buzz is high given the earnings event, but social coverage in the packet is unavailable and should not be treated as confirmatory. The packet's initial peer list is medtech-heavy and not a good operating comp set for Humana; managed-care peers such as UnitedHealth, CVS/Aetna, Elevance, and Centene are more relevant for MA rates, benefit design, membership, and medical-cost trend. Analyst revision evidence is still thin at this stage, so the memo should stay in monitoring mode until post-print estimate and target changes become clearer.

RankAlpha Sentiment Codex - 2026-04-29

Open full AI memo

Evidence flagged

peer set is too generic or lacks enough direct operating comparators

Impact

tentative

Confidence

AI events

2026-04-29eventQ1 beat was offset by no adjusted-guide raise and a lower GAAP EPS floorMedium impact

Humana reported 1Q26 adjusted EPS of 10.31, with the insurance benefit ratio at 89.4%, slightly better than guidance, but it only affirmed adjusted FY2026 EPS of at least 9.00 while cutting GAAP EPS guidance to at least 8.36 from at least 8.89; management also said the company still sees a persistent gap between 2027 MA rates and medical cost trend [#8-K-2026-04-29].

2026-07-29catalystQ2 medical cost trend and benefit ratio will test whether the strong Q1 start is durableHigh impact

Prepared remarks said medical and pharmacy cost trends were slightly better than expected so far, with 2Q insurance benefit ratio expected to be slightly above 91% and Q2 earnings expected at roughly 80% to 85% of FY2026 adjusted earnings; a clean follow-through would support confidence that 2026 is tracking to plan [#8-K-2026-04-29].

2028-12-31catalystMA membership growth and CenterWell scale remain the main 2027-2028 recovery setupHigh impact

Management said individual MA membership was up about 22% year to date and still targets about 25% growth for FY2026, while CenterWell primary care added about 110,500 patients in Q1; management framed the expanded membership base, Stars improvement work, and pricing discipline as the path to unlocking earnings potential by 2028 [#8-K-2026-04-29].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-04-29 • Updated nightlySource: Internal modelMethodology